Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study
This letter to the editor summarises a study used to assess the impact of erythropoiesis-stimulating agents (ESA) treatment on overall survival and on the evolution of MDS into acute myeloid leukaemia.
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
This Phase 3 randomized double-blind placebo controlled study demonstrated that treatment with luspatercept resulted in a significantly reduced transfusion burden compared with placebo. Luspatercept is thought to work by accelerating the maturation of red cells, thus reducing red blood cell transfusion requirements in patients with anaemia due to IPSS-R very low-, low-, or intermediate-risk MDS with ring sideroblasts who require red blood cell transfusions.
Update on the pathologic diagnosis of chronic myelomonocytic Leukemia
Daniel A. Arber Attillio Orazi
This is a review of the current diagnostic criteria for chronic myelomonocytic leukaemia which now incorporates the use of molecular genetic studies, helping to inform prognosis.
Targeting TP53 Mutations in Myelodysplastic Syndromes
David Sallman, MD
Assistant Member, Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
Minimal residual disease monitoring in haematological malignancies is seen as standard of care in the evaluation of response to treatment and the prediction of relapse risk. This article considers the potential benefit of molecular monitoring after transplantation for myelodysplastic syndrome.